Biography
Charles M. Perou, PhD is currently the Co-Director of the Computational Medicine Program, Faculty Director of the Lineberger Comprehensive Cancer Center (LCCC) Bioinformatics Group, and Co-Leader of the LCCC Breast Cancer Research Program at UNC. He is also a member of the ALLIANCE Breast Committee, and the Executive Steering Committee Member of the Translational Breast Cancer Research Consortium (TBCRC). Dr. Perou co-founded 3 biotechnology companies (Bioclassifier, GeneCentric Therapeutics, and Reveal Genomics), which are broadly focused on using genomic assays coupled to novel therapeutics to make improvements for personalized patient care and ultimately to improve cancer patient survival outcomes. His training history includes a Bachelor's degree in Biology from Bates College, a PhD in Experimental Pathology from the University of Utah, and postdoctoral work in the laboratory of David Botstein (then at Stanford University). He won a number of awards including the European Institute of Oncology Breast Cancer Therapy Award, the Jill Rose Award for Distinguished Biomedical Research from BCRF, the Brinker Award for Scientific Distinction from Komen, the Distinguished Scientist Award from the Association of American Cancer Institutes, and most recently been elected as a Fellow of the AACR (FAACR). He authored more than 450 peer reviewed articles, and has been named an inventor on multiple USA and European patents. Lastly, He has been named a Thomson Reuters Most Highly Cited Researcher in 2014-2022, where his work has received more than 240,000 total citations according to Google Scholar.